Stay updated on Pembrolizumab in CAR T Failure Lymphomas Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in CAR T Failure Lymphomas Clinical Trial page.

Latest updates to the Pembrolizumab in CAR T Failure Lymphomas Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedMajor change: page now carries a government-operating-status notice and a new version tag (v3.2.0) replacing the old one (v3.1.0).SummaryDifference4%
- Check21 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0. The change is limited to the revision label; no core content or critical data appears to be altered.SummaryDifference0.1%
- Check28 days agoNo Change Detected
- Check35 days agoChange DetectedRevision: v3.0.2 replaces v3.0.1, and the 'Back to Top' element has been removed.SummaryDifference0.2%
- Check43 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check50 days agoChange DetectedThe web page has added a facility name and location related to Hemic and Lymphatic Diseases, specifically mentioning Lymphoma, Follicular, and pembrolizumab, while removing various related terms and resources.SummaryDifference4%
- Check57 days agoChange DetectedThere are no significant changes to the web page content.SummaryDifference0.4%
Stay in the know with updates to Pembrolizumab in CAR T Failure Lymphomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in CAR T Failure Lymphomas Clinical Trial page.